20% Solution: Addressing the Biotech/Pharma Logjam with Innovation Partnerships
While pharma needs to access biotech's innovation, biotechs and their investors are unwilling to cede late-stage control. This is a recipe for stalemate: the industry needs different partnership structures which fully pay biotech for innovation (with royalties of 20% or more) and leave early-stage development in their hands, while allowing Big Pharma to do the later-stage development and commercialization. To afford these deals, however, Pharma needs to cut their own spending on innovation.
John Maraganore, PhD, President and CEO, Alnylam Pharmaceuticals
Inc.
If Big Pharma’s late-stage pipelines are any indication,
the drug industry is starving for innovation.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.